Learn Before
Concept
Darunavir/cobicistat
- Brand Name: Prezcobix (US), Rezolsta (EU)
- Indication: HIV-1 treatment
- Class: protease inhibitor, CYP450 inhibitor
- Mechanism: Darunavir inhibits the HIV-1 protease from forming a dimer and becoming active. Cobicistat inhibits the activity of CYP450 3A to increase the amount of darunavir in the blood. The drug ultimately inhibits the maturation of the virus.
- Common AEs: GI adverse events (nausea, vomiting), headache
- Drug-Drug Interactions: Colchicine and strong inhibitors of CYP3A and Pâglycoprotein
- Safety and Efficacy: Preclinical studies showed the treatment had an inhibitory effect in COVID-19. This combination of medications was well tolerated in COVID-19 patients. A clinical trial showed that viral clearance when treated with darunavir/cobicistat was comparable to the control, in which patients received no oral antiviral medication, and did not seem to increase the amount of negative test results for COVID-19 after treatment.
0
1
Updated 2021-04-30
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences